Header Logo

Connection

Lynn Morris to Cohort Studies

This is a "connection" page, showing publications Lynn Morris has written about Cohort Studies.
Connection Strength

0,627
  1. HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
    View in: PubMed
    Score: 0,141
  2. Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS. 2016 Apr 24; 30(7):1005-14.
    View in: PubMed
    Score: 0,106
  3. Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):204-15.
    View in: PubMed
    Score: 0,056
  4. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J Med Virol. 2006 Oct; 78(10):1262-8.
    View in: PubMed
    Score: 0,055
  5. Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. Front Immunol. 2019; 10:1497.
    View in: PubMed
    Score: 0,033
  6. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148.
    View in: PubMed
    Score: 0,028
  7. Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS One. 2015; 10(7):e0131906.
    View in: PubMed
    Score: 0,025
  8. Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. J Infect Dis. 2015 May 01; 211(9):1461-6.
    View in: PubMed
    Score: 0,024
  9. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-61.
    View in: PubMed
    Score: 0,024
  10. Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health. 2014 Feb; 19(2):236-9.
    View in: PubMed
    Score: 0,023
  11. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,022
  12. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33.
    View in: PubMed
    Score: 0,022
  13. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,019
  14. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health. 2011 Feb 08; 11:88.
    View in: PubMed
    Score: 0,018
  15. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology. 2009 Mar 15; 385(2):505-20.
    View in: PubMed
    Score: 0,016
  16. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One. 2008 Apr 16; 3(4):e1954.
    View in: PubMed
    Score: 0,015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.